Status:
COMPLETED
Control of Pain in Intravitreal Injections Using Topical NSAIDs
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Intravitreal Injections
IVI
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Intravitreal injections (IVI) are a common form of treatment for multiple retinal pathologies. The investigators hypothesize that an intervention with a topical NSAID will alleviate pain experienced a...
Detailed Description
Intravitreal injections are a very common form of treatment for a variety of ocular pathologies. The use of these injections has only increased given the large utility they provide. They both improved...
Eligibility Criteria
Inclusion
- Eyes with retinal pathology requiring anti-VEGF therapy
- Previously had an IVI
Exclusion
- History of previous eye surgery other than cataract extraction
- Herpetic eye disease
- Uncontrolled glaucoma
- Uveitis
- Acute conjunctivitis
- Pregnancy
- Known previous adverse response or contraindication to intravitreal injection, Bromfenac, or other NSAIDs.
- Keratitis including povidone-induced keratitis
- Bullous keratopathy
- Diagnosis of dry eye syndrome
- Uncontrolled diabetes
- NSAID use 3 days prior to IVI
Key Trial Info
Start Date :
June 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 19 2019
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04343222
Start Date
June 27 2019
End Date
December 19 2019
Last Update
June 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792